These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 30169876)

  • 1. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indolent course of brainstem tumors with K27M-H3.3 mutation.
    Baroni LV; Solano-Paez P; Nobre L; Michaeli O; Hawkins C; Laughlin S; Bartels U; Ramaswamy V; Bouffet E
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28102. PubMed ID: 31793190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
    Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
    Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.
    Lin GL; Nagaraja S; Filbin MG; Suvà ML; Vogel H; Monje M
    Acta Neuropathol Commun; 2018 Jun; 6(1):51. PubMed ID: 29954445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC).
    Fonseca A; Afzal S; Bowes L; Crooks B; Larouche V; Jabado N; Perreault S; Johnston DL; Zelcer S; Fleming A; Scheinemann K; Silva M; Vanan MI; Mpofu C; Wilson B; Eisenstat DD; Lafay-Cousin L; Hukin J; Hawkins C; Bartels U; Bouffet E
    J Neurooncol; 2020 Aug; 149(1):45-54. PubMed ID: 32632896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
    Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
    Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
    Dalle Ore C; Coleman C; Gupta N; Mueller S
    Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets.
    Aziz-Bose R; Monje M
    Curr Opin Oncol; 2019 Nov; 31(6):522-530. PubMed ID: 31464759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
    Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
    Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma.
    Price G; Bouras A; Hambardzumyan D; Hadjipanayis CG
    EBioMedicine; 2021 Jul; 69():103453. PubMed ID: 34157482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.
    Mendez F; Kadiyala P; Nunez FJ; Carney S; Nunez FM; Gauss JC; Ravindran R; Pawar S; Edwards M; Garcia-Fabiani MB; Haase S; Lowenstein PR; Castro MG
    Clin Cancer Res; 2020 Aug; 26(15):4080-4092. PubMed ID: 32332014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.
    Patel SK; Hartley RM; Wei X; Furnish R; Escobar-Riquelme F; Bear H; Choi K; Fuller C; Phoenix TN
    Neuro Oncol; 2020 Mar; 22(3):381-392. PubMed ID: 31638150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas.
    Schramm K; Iskar M; Statz B; Jäger N; Haag D; Słabicki M; Pfister SM; Zapatka M; Gronych J; Jones DTW; Lichter P
    Neuro Oncol; 2019 Jul; 21(7):867-877. PubMed ID: 30943283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
    Su JM; Murray JC; McNall-Knapp RY; Bowers DC; Shah S; Adesina AM; Paulino AC; Jo E; Mo Q; Baxter PA; Blaney SM
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28283. PubMed ID: 32285998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
    van den Bent M; Saratsis AM; Geurts M; Franceschi E
    Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
    Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
    Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.
    Schuelke MR; Wongthida P; Thompson J; Kottke T; Driscoll CB; Huff AL; Shim KG; Coffey M; Pulido J; Evgin L; Vile RG
    J Immunother Cancer; 2019 Jul; 7(1):188. PubMed ID: 31315671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.